BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Agilent, SomaLogic sign agreement for supply of custom microarrays

02 May 2019 | News

Use of Agilent's custom microarrays in the SOMAscan assay will help drive biomarker discovery efforts as well as novel diagnostics and accelerated pharmaceutical development

Agilent Technologies and SomaLogic have announced a multi-year supply agreement whereby Agilent will supply customized high-fidelity oligo microarrays for use in the nucleic acid detection step within SomaLogic's novel SOMAscan assay, a protein measurement platform with applications across basic and clinical research, diagnostics, and pharmaceutical discovery and development.

SomaLogic's SOMAscan assay solves a protein measurement challenge using a DNA measurement solution, enabling the accurate measurement of an individual's protein makeup with unequalled sensitivity and dynamic range. The customized Agilent microarray, which is based on SomaLogic's specifications, is incorporated into the SOMAscan assay which is used to detect and measure 5,000 proteins accurately and reproducibly from a small volume of biological sample.

"Agilent and SomaLogic have developed a mutually rewarding partnership over the years, and we are pleased that they will continue to leverage our microarray platform as they scale up their business," said Sam Raha, president of Agilent's Diagnostics and Genomics Group. "Agilent's microarray platform has demonstrated superiority for measurement of DNA and RNA at scale and it is exciting to see how SomaLogic is creatively applying this capability to measure thousands of proteins in a single assay."

"To date we have analyzed over 300,000 human samples as we have built the SOMAscan platform," said Roy Smythe, CEO of SomaLogic. "Agilent custom microarrays have been a critical part of our success to date, and as we now move into health, wellness and disease-monitoring applications for our technology they continue to be an extremely high quality and scalable solution."

Specific details of the agreement were not disclosed.